Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $1.5 billion.

  • Ligand Pharmaceuticals' Liabilities and Shareholders Equity rose 5465.75% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 billion, marking a year-over-year increase of 2129.91%. This contributed to the annual value of $941.8 million for FY2024, which is 1963.35% up from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Liabilities and Shareholders Equity is $1.5 billion, which was up 5465.75% from $948.6 million recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Liabilities and Shareholders Equity peaked at $1.5 billion during Q3 2025, and registered a low of $758.1 million during Q2 2023.
  • In the last 5 years, Ligand Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $948.6 million in 2025 and averaged $1.0 billion.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Liabilities and Shareholders Equity tumbled by 4122.43% in 2022, and later soared by 5465.75% in 2025.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Liabilities and Shareholders Equity stood at $1.3 billion in 2021, then crashed by 41.22% to $762.7 million in 2022, then increased by 3.22% to $787.2 million in 2023, then increased by 19.63% to $941.8 million in 2024, then skyrocketed by 56.81% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q3 2025, $948.6 million for Q2 2025, and $905.4 million during Q1 2025.